Drug Profile
Somatropin pegylated - GeneScience Pharmaceuticals
Alternative Names: GenSci-004; JINTOPIN AQ; Jintrolong®; Jintropin; Jintropin AQ; PEG-rhGH - GeneScience Pharmaceuticals; PEG-somatropin; Recombinant human growth hormone - GeneScience PharmaceuticalsLatest Information Update: 29 Mar 2024
Price :
$50
*
At a glance
- Originator GeneScience Pharmaceuticals
- Developer First Hospital of Jilin University; GeneScience Pharmaceuticals; Nanjing Medical University; Shanghai Jiao Tong University; Zhejiang University
- Class Growth hormones; Hormonal replacements; Obesity therapies; Recombinant proteins
- Mechanism of Action Human growth hormone replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Somatotropin deficiency
- Phase III Prader-Willi syndrome; Short stature
- Phase II Turner's syndrome
Most Recent Events
- 21 Mar 2024 GeneScience Pharmaceutical plans a phase I bioequivalence trial (In volunteers, In adults) in China (SC, Injection) in April 2024 (NCT06331026)
- 18 Nov 2023 GeneScience Pharmaceuticals plans a phase I trial for Somatotropin deficiency (In volunteers) in China (SC, Injection) (NCT06135155)
- 18 Nov 2023 GeneScience Pharmaceuticals plans a phase I trial for Somatotropin deficiency (In volunteers) in China (SC, Injection) (NCT06135168)